HOOK
HOOKIPA Pharma Inc.
Price Chart
Latest Quote
$1.15
+0.00 (+0.00%)
Current Price
| Previous Close | $1.15 |
| Open | $1.09 |
| Day High | $1.15 |
| Day Low | $1.09 |
| Volume | 315 |
Stock Information
| Shares Outstanding | 9.98M |
| Total Debt | $596K |
| Cash Equivalents | $40.28M |
| Revenue | $9.35M |
| Net Income | $-73.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.23M |
| EPS (TTM) | $-4.83 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-25.11M |
| Sales | $9.35M |
| Income | $-73.31M |
| Book/sh | $2.71 |
| Cash/sh | $4.04 |
| Employees | 82 |
Financial Ratios
| Quick Ratio | 2.92 |
| Current Ratio | 3.61 |
| Debt/Eq | 1.75 |
Returns & Margins
| ROA | -45.20% |
| ROE | -105.79% |
| Operating Margin | -885.28% |
Ownership
| Insider Ownership | 0.12% |
| Institutional Ownership | 3.16% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.21 |
| P/S | 1.52 |
| P/B | 0.42 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.15 |
| SMA50 | $1.16 |
| SMA200 | $1.00 |
| RSI | 100.00 |
| ATR | 0.0068 |
| Shares Float | 12.34M |
| Short Float | 0.45% |
| Short Ratio | 0.57 |
| Volatility | 0.83 |
Performance History
| Week | +0.00% |
| Month | -3.36% |
| Quarter | +6.48% |
| 6 Months | +32.79% |
| YTD | +28.49% |
| Year | -12.21% |
| 3 Years | -88.73% |
| 5 Years | -98.84% |
| 10 Years | -99.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.15 | 0 |
| 2026-06-17 | $1.15 | 0 |
| 2026-06-16 | $1.15 | 0 |
| 2026-06-15 | $1.15 | 0 |
| 2026-06-12 | $1.15 | 0 |
| 2026-06-11 | $1.15 | 0 |
| 2026-06-10 | $1.15 | 0 |
| 2026-06-09 | $1.15 | 0 |
| 2026-06-08 | $1.15 | 0 |
| 2026-06-05 | $1.15 | 0 |
| 2026-06-04 | $1.15 | 0 |
| 2026-06-03 | $1.15 | 0 |
| 2026-06-02 | $1.15 | 431 |
| 2026-06-01 | $1.14 | 6,016 |
| 2026-05-29 | $1.14 | 21,372 |
| 2026-05-28 | $1.13 | 5,048 |
| 2026-05-27 | $1.17 | 2,873 |
| 2026-05-26 | $1.18 | 65,007 |
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
đ° Latest News
No news articles available at the moment. Check back later for updates on HOOK.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $43,946,000 | $20,129,000 | $14,249,000 | $18,448,000 |
| Operating Revenue | $43,946,000 | $20,129,000 | $14,249,000 | $18,448,000 |
| Expenses | ||||
| Interest Expense | $2,000 | $317,000 | $687,000 | $898,000 |
| Total Expenses | $81,337,000 | $93,864,000 | $79,488,000 | $90,398,000 |
| Other Income Expense | $-9,917,000 | $-12,453,000 | $-392,000 | $-2,843,000 |
| Other Non Operating Income Expenses | $-3,249,000 | $313,000 | $-392,000 | $-2,843,000 |
| Net Non Operating Interest Income Expense | $3,699,000 | $4,976,000 | $946,000 | $-871,000 |
| Interest Expense Non Operating | $2,000 | $317,000 | $687,000 | $898,000 |
| Operating Expense | $81,337,000 | $93,864,000 | $79,488,000 | $90,398,000 |
| Other Operating Expenses | $-7,396,000 | $-11,193,000 | $-7,916,000 | $-9,724,000 |
| General And Administrative Expense | - | - | $18,759,000 | $17,269,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Net Interest Income | $3,699,000 | $4,976,000 | $946,000 | $-871,000 |
| Interest Income | $3,701,000 | $5,293,000 | $1,633,000 | $27,000 |
| Normalized Income | $-36,848,336 | $-71,494,860 | $-64,915,000 | $-75,665,000 |
| Net Income From Continuing And Discontinued Operation | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Total Operating Income As Reported | $-51,455,000 | $-97,694,000 | $-73,155,000 | $-81,674,000 |
| Net Income Common Stockholders | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Net Income | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Net Income Including Noncontrolling Interests | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Net Income Continuous Operations | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Pretax Income | $-43,609,000 | $-81,212,000 | $-64,685,000 | $-75,664,000 |
| Special Income Charges | $-6,668,000 | $-12,766,000 | $0 | $0 |
| Interest Income Non Operating | $3,701,000 | $5,293,000 | $1,633,000 | $27,000 |
| Operating Income | $-37,391,000 | $-73,735,000 | $-65,239,000 | $-71,950,000 |
| Per Share | ||||
| Diluted EPS | $-3.47 | $-8.63 | $-9.90 | $-23.00 |
| Basic EPS | $-3.47 | $-8.63 | $-9.90 | $-23.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $-13,336 | $-2,680,860 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-34,186,000 | $-64,577,000 | $-60,396,000 | $-70,126,000 |
| Total Unusual Items | $-6,668,000 | $-12,766,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-6,668,000 | $-12,766,000 | $0 | $0 |
| Reconciled Depreciation | $2,753,000 | $3,552,000 | $3,602,000 | $4,640,000 |
| EBITDA (Bullshit earnings) | $-40,854,000 | $-77,343,000 | $-60,396,000 | $-70,126,000 |
| EBIT | $-43,607,000 | $-80,895,000 | $-63,998,000 | $-74,766,000 |
| Diluted Average Shares | $12,538,794 | $9,452,657 | $6,557,071 | $6,558,080 |
| Basic Average Shares | $12,538,794 | $9,452,657 | $6,557,071 | $6,558,080 |
| Diluted NI Availto Com Stockholders | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Tax Provision | $-106,000 | $368,000 | $230,000 | $1,000 |
| Write Off | $4,004,000 | $12,766,000 | $0 | $0 |
| Restructuring And Mergern Acquisition | $2,664,000 | $0 | $0 | - |
| Research And Development | $68,507,000 | $86,424,000 | $68,645,000 | $82,853,000 |
| Selling General And Administration | $20,226,000 | $18,633,000 | $18,759,000 | $17,269,000 |
| Other Gand A | - | - | $18,759,000 | $17,269,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $51,214,000 | $89,857,000 | $102,517,000 | $89,592,000 |
| Total Assets | $82,545,000 | $161,337,000 | $170,454,000 | $126,045,000 |
| Total Non Current Assets | $1,880,000 | $14,221,000 | $23,258,000 | $23,910,000 |
| Other Non Current Assets | $816,000 | $1,006,000 | $1,282,000 | $1,795,000 |
| Current Assets | $80,665,000 | $147,116,000 | $147,196,000 | $102,135,000 |
| Other Current Assets | $14,997,000 | $10,749,000 | $12,159,000 | $14,482,000 |
| Assets Held For Sale Current | $2,216,000 | $0 | - | - |
| Restricted Cash | $98,000 | $0 | $537,000 | $566,000 |
| Receivables | $23,670,000 | $19,271,000 | $22,012,000 | $21,166,000 |
| Other Receivables | $23,380,000 | $18,760,000 | $15,479,000 | $14,271,000 |
| Accounts Receivable | $290,000 | $511,000 | $6,533,000 | $6,895,000 |
| Cash Cash Equivalents And Short Term Investments | $39,684,000 | $117,096,000 | $112,488,000 | $65,921,000 |
| Cash And Cash Equivalents | $39,684,000 | $117,096,000 | $112,488,000 | $65,921,000 |
| Prepaid Assets | - | - | - | $14,482,000 |
| Debt | ||||
| Total Debt | $875,000 | $6,559,000 | $6,503,000 | $10,625,000 |
| Long Term Debt And Capital Lease Obligation | $323,000 | $3,801,000 | $3,221,000 | $6,130,000 |
| Current Debt And Capital Lease Obligation | $552,000 | $2,758,000 | $3,282,000 | $4,495,000 |
| Current Debt | - | $1,120,000 | $1,594,000 | $2,792,000 |
| Other Current Borrowings | - | $1,120,000 | $1,594,000 | $2,792,000 |
| Long Term Debt | - | - | $911,000 | $2,219,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $31,331,000 | $71,480,000 | $67,937,000 | $36,453,000 |
| Total Non Current Liabilities Net Minority Interest | $6,678,000 | $29,492,000 | $32,305,000 | $8,799,000 |
| Other Non Current Liabilities | $5,630,000 | $6,017,000 | $3,420,000 | $2,648,000 |
| Non Current Deferred Liabilities | $725,000 | $19,674,000 | $25,664,000 | $21,000 |
| Current Liabilities | $24,653,000 | $41,988,000 | $35,632,000 | $27,654,000 |
| Current Deferred Liabilities | $4,762,000 | $14,683,000 | $15,984,000 | $6,231,000 |
| Payables And Accrued Expenses | $19,339,000 | $24,547,000 | $16,366,000 | $16,928,000 |
| Payables | $8,687,000 | $12,865,000 | $5,718,000 | $8,762,000 |
| Total Tax Payable | $0 | $367,000 | $230,000 | $0 |
| Income Tax Payable | $0 | $367,000 | $230,000 | $0 |
| Accounts Payable | $8,687,000 | $12,498,000 | $5,488,000 | $8,762,000 |
| Equity | ||||
| Common Stock Equity | $51,214,000 | $89,857,000 | $102,517,000 | $89,592,000 |
| Total Equity Gross Minority Interest | $51,214,000 | $89,857,000 | $102,517,000 | $89,592,000 |
| Stockholders Equity | $51,214,000 | $89,857,000 | $102,517,000 | $89,592,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,087,000 | $-7,933,000 | $-7,156,000 | $-4,780,000 |
| Other Equity Adjustments | $-5,087,000 | $-7,933,000 | $-7,156,000 | $-4,780,000 |
| Retained Earnings | $-412,764,000 | $-369,261,000 | $-287,681,000 | $-222,766,000 |
| Other | ||||
| Ordinary Shares Number | $12,054,539 | $12,054,576 | $7,631,230 | $6,558,080 |
| Share Issued | $12,054,539 | $12,054,576 | $7,631,230 | $6,558,080 |
| Tangible Book Value | $51,214,000 | $89,857,000 | $102,517,000 | $89,592,000 |
| Invested Capital | $51,214,000 | $90,977,000 | $105,022,000 | $94,603,000 |
| Working Capital | $56,012,000 | $105,128,000 | $111,564,000 | $74,481,000 |
| Capital Lease Obligations | $875,000 | $5,439,000 | $3,998,000 | $5,614,000 |
| Total Capitalization | $51,214,000 | $89,857,000 | $103,428,000 | $91,811,000 |
| Additional Paid In Capital | $469,064,000 | $467,050,000 | $397,349,000 | $317,135,000 |
| Capital Stock | $1,000 | $1,000 | $5,000 | $3,000 |
| Common Stock | $1,000 | $1,000 | $5,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $725,000 | $19,674,000 | $25,664,000 | $21,000 |
| Long Term Capital Lease Obligation | $323,000 | $3,801,000 | $2,310,000 | $3,911,000 |
| Current Deferred Revenue | $4,762,000 | $14,683,000 | $15,984,000 | $6,231,000 |
| Current Capital Lease Obligation | $552,000 | $1,638,000 | $1,688,000 | $1,703,000 |
| Current Accrued Expenses | $10,652,000 | $11,682,000 | $10,648,000 | $8,166,000 |
| Net PPE | $1,064,000 | $13,215,000 | $21,976,000 | $22,115,000 |
| Accumulated Depreciation | $-5,886,000 | $-9,823,000 | $-7,779,000 | $-6,366,000 |
| Gross PPE | $6,950,000 | $23,038,000 | $29,755,000 | $28,481,000 |
| Leases | $3,095,000 | $3,300,000 | $3,164,000 | $3,348,000 |
| Construction In Progress | $8,000 | $212,000 | $10,567,000 | $7,746,000 |
| Other Properties | $885,000 | $14,195,000 | $11,409,000 | $12,788,000 |
| Machinery Furniture Equipment | $2,962,000 | $3,306,000 | $2,656,000 | $2,527,000 |
| Land And Improvements | $0 | $2,025,000 | $1,959,000 | $2,072,000 |
| Properties | $0 | $0 | $0 | $0 |
| Treasury Shares Number | - | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | $267,000 | $250,000 |
| Buildings And Improvements | - | - | - | $5,763,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-77,172,000 | $-61,683,000 | $-25,014,000 | $-78,597,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-76,978,000 | $-57,524,000 | $-19,997,000 | $-66,016,000 |
| Cash Flow From Continuing Operating Activities | $-76,978,000 | $-57,524,000 | $-19,997,000 | $-66,016,000 |
| Investing Activities | ||||
| Capital Expenditure | $-194,000 | $-4,159,000 | $-5,017,000 | $-12,581,000 |
| Investing Cash Flow | $-194,000 | $-4,159,000 | $-5,017,000 | $-12,581,000 |
| Cash Flow From Continuing Investing Activities | $-194,000 | $-4,159,000 | $-5,017,000 | $-12,581,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $67,573,000 | $75,316,000 | $203,000 |
| Financing Cash Flow | $-1,276,000 | $65,670,000 | $72,271,000 | $-235,000 |
| Cash Flow From Continuing Financing Activities | $-1,276,000 | $65,670,000 | $72,271,000 | $-235,000 |
| Net Other Financing Charges | $-135,000 | $-149,000 | $-195,000 | - |
| Net Preferred Stock Issuance | $0 | $18,530,000 | $29,625,000 | $0 |
| Preferred Stock Issuance | $0 | $18,530,000 | $29,625,000 | $0 |
| Net Common Stock Issuance | $0 | $49,043,000 | $45,691,000 | $203,000 |
| Common Stock Issuance | $0 | $49,043,000 | $45,691,000 | $203,000 |
| Other | ||||
| Repayment Of Debt | $-1,141,000 | $-1,754,000 | $-2,850,000 | $-438,000 |
| Interest Paid Supplemental Data | $2,000 | $14,000 | $32,000 | $48,000 |
| Income Tax Paid Supplemental Data | $1,000 | $403,000 | $1,000 | $1,000 |
| End Cash Position | $39,886,000 | $117,521,000 | $113,444,000 | $66,912,000 |
| Beginning Cash Position | $117,521,000 | $113,444,000 | $66,912,000 | $143,177,000 |
| Effect Of Exchange Rate Changes | $813,000 | $90,000 | $-725,000 | $2,567,000 |
| Changes In Cash | $-78,448,000 | $3,987,000 | $47,257,000 | $-78,832,000 |
| Net Issuance Payments Of Debt | $-1,141,000 | $-1,754,000 | $-2,850,000 | $-438,000 |
| Net Long Term Debt Issuance | $-1,141,000 | $-1,754,000 | $-2,850,000 | $-438,000 |
| Long Term Debt Payments | $-1,141,000 | $-1,754,000 | $-2,850,000 | $-438,000 |
| Net PPE Purchase And Sale | $-194,000 | $-4,159,000 | $-5,017,000 | $-12,581,000 |
| Purchase Of PPE | $-194,000 | $-4,159,000 | $-5,017,000 | $-12,581,000 |
| Change In Working Capital | $-42,246,000 | $5,329,000 | $36,113,000 | $-3,861,000 |
| Change In Other Working Capital | $-27,538,000 | $-8,258,000 | $35,508,000 | $1,422,000 |
| Change In Other Current Liabilities | $-1,591,000 | $1,105,000 | $-38,000 | $-2,004,000 |
| Change In Payables And Accrued Expense | $-2,398,000 | $6,989,000 | $511,000 | $5,634,000 |
| Change In Accrued Expense | $-828,000 | $490,000 | $2,510,000 | $4,776,000 |
| Change In Payable | $-1,570,000 | $6,499,000 | $-1,999,000 | $858,000 |
| Change In Account Payable | $-1,570,000 | $6,499,000 | $-1,999,000 | $858,000 |
| Change In Prepaid Assets | $-5,255,000 | $2,039,000 | $2,431,000 | $-7,091,000 |
| Change In Receivables | $-5,464,000 | $3,454,000 | $-2,299,000 | $-2,238,000 |
| Changes In Account Receivables | $524,000 | $6,180,000 | $-341,000 | $-1,943,000 |
| Stock Based Compensation | $2,014,000 | $2,345,000 | $5,043,000 | $7,644,000 |
| Asset Impairment Charge | $4,004,000 | $12,766,000 | $0 | $0 |
| Depreciation Amortization Depletion | $2,753,000 | $3,552,000 | $3,602,000 | $4,640,000 |
| Depreciation And Amortization | $2,753,000 | $3,552,000 | $3,602,000 | $4,640,000 |
| Net Income From Continuing Operations | $-43,503,000 | $-81,580,000 | $-64,915,000 | $-75,665,000 |
| Change In Other Current Assets | - | $304,000 | $424,000 | $416,000 |
| Other Non Cash Items | - | $64,000 | $160,000 | $1,226,000 |
Fetched: 2026-02-02